Gapping up
In reaction to earnings/guidance:
- AYX +24.3% (guides higher, names new CEO), AMSC +9.6% (guides SepQ and DecQ revs above consensus; acquires Northeast Power Systems), HIMX +9%, GPI +7.3% (comps), WING +5.4% (comps), ALXN +2%, FRGI +0.9% (Q3 comps)
M&A news:
- TXG +2.9% (to acquire ReadCoor)
- GNRC +1.7% (to acquire Enbala Power Networks)
- IIIV +1.7% (acquires three companies)
- AVLR +0.9% (to acquire Transaction Tax Resources)
Other news:
- EEX +18.5% (announces $20 mln stock repurchase authorization)
- BNTX +8.9% (BioNTech and Pfizer (PFE) begin rolling submission to EMA for SARS-CoV-2 vaccine candidate BNT162b2)
- GLYC +7.6% (FDA grants a Rare Pediatric Disease designation for rivipansel)
- FCEL +6.3% (disputes claims of short seller)
- AMPH +5.9% (receives FDA approval for atropine sulfate injection)
- SMMT +5% (files for $200 mln mixed securities shelf offering)
- CDXC +4.7% (announces study results showing nutritional protocol including nicotinamide riboside plus standard of care reduces recovery time in COVID-19 patients by nearly 30%)
- VEC +3.7% (awarded $196 mln contract for Guantanamo Bay)
- BGNE +3.1% (following acquisition of 5% interest held by JV partner)
- WSR +3% (reports Q3-2020 rental collections of 90%)
- SMCI +2% (to support the new NVIDIA BlueField-2 DPU)
- OR +1.8% (reports multiple new high-grade gold discoveries at Cariboo Gold Project)
- PFE +1.4% (BioNTech and Pfizer (PFE) begin rolling submission to EMA for SARS-CoV-2 vaccine candidate BNT162b2)
- QTRX +1.1% (license agreement with ABT)
Analyst comments:
- SEAS +5% (upgraded to Outperform from Neutral at Credit Suisse)
- BCS +3.7% (upgraded to Buy from Sell at Redburn)
- TSE +3.3% (upgraded to Buy from Hold at Jefferies)
- FISV +2.2% (upgraded to Outperform from Neutral at Credit Suisse)
- AAP +2% (upgraded to Overweight from Neutral at JP Morgan)
- NOC +1.7% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)
- SYNH +1.4% (upgraded to Buy from Neutral at Mizuho)
- BMO +1.3% (upgraded to Neutral from Underperform at BofA Securities)
- BECN +1.2% (upgraded to Outperform from Mkt Perform at William Blair)
- COST +1% (upgraded to Overweight from Equal Weight at Barclays)